Table 1 Demographic and clinical data of the patient population at baseline.

From: Association between anticoagulation strategy and quality of life in chronic hemodialysis patients

Gender (M/F)

38 M/32 F

Age (years)

60.0 ± 17.9

Dry body weight (kg)

76.4 ± 18.9

Renal disease

Glomerulonephritis (n = 18); diabetes mellitus (n = 11); renal vascular disease (n = 10); ADPKD (n = 9); other (n = 22)

Vascular access

Arterio-venous fistula (n = 49); central venous catheter (n = 21)

Anticoagulation dose

Tinzaparin 3500 (n = 17)

Enoxaparin 20 mg (n = 12); 40 mg (n = 28); 60 mg (n = 7); 80 mg (n = 1)

Fondaparinux (n = 1)

No anticoagulation (n = 4)

Platelet inhibitors

Acetylsalicylic acid (n = 26); clopidogrel (n = 6); dual antiplatelet (n = 4); coumarin (n = 2)

Hb (g/dL)

10.9 ± 1.4

Platelets count (103/µL)

217 ± 75

aPTT (s)

34.5 [32.6; 38.1]

INR (–)

0.98 [0.93; 1.03]

CRP (mg/L)

4.2 [1.4; 10.9]

  1. Hb hemoglobin, aPTT activated partial thromboplastin time, INR international normalized ratio, CRP C-reactive protein, ADPKD autosomal dominant polycystic kidney disease.
Back to article page